Expanding our Potential via Strategic Collaborations
Collaborations are an important means to executing on our strategy and develop drug candidates that can bring best-in-class therapies to patients.
If you or your company are interested in collaboration and partnering opportunities, contact us.
BeiGene, Ltd. – Zandelisib Clinical Collaboration
In October 2018, we announced a clinical collaboration with BeiGene, Ltd. to evaluate the safety and efficacy of zandelisib (ME-401) in combination with BeiGene’s zanubrutinib, an investigational inhibitor of Bruton’s tyrosine kinase (“BTK”), for the treatment of patients with B-cell malignancies. Study costs will be shared equally by the parties, and we will supply zandelisib and BeiGene will supply zanubrutinib. We retain full commercial rights for zandelisib and BeiGene retains full commercial rights for zanubrutinib.